Healthy
Conditions
Keywords
gene expression, essential oils, gut microbiome
Brief summary
This study aims to evaluate the efficacy of specific essential oils. Efficacy will be evaluated through changes, if any, to hsCRP, gene expression, and standard hematologic and metabolic parameters, as well as subjective health changes as measured by Gastrointestinal Symptom Rating Scale (GSRS), PROMIS Global Health survey, PROMIS Fatigue Scale, Immune Fitness Item Scale (IFIS), and the Immune Status Questionnaire (ISQ) in healthy volunteers. The main questions it aims to answer are: 1. Do specific essential oils affect gene expression and hematologic and metabolic parameters as measured in blood? 2. How do essential oils affect gut microbiome? 3. How does daily use of specific essential oils affect subjective quality of life and health parameters? 4. Is ingesting and topically applying specific essential oils daily safe, as measured by laboratory tests and adverse events? Two study products will be used: oil for topical use, supplement for internal use. The two products will be used together and compared to a placebo group. The topical oil contains a blend of ginger essential oil, peppermint essential oil, caraway essential oil, coriander essential oil, and anise essential oil. The supplement contains everything the oil has, plus anise essential oil. Participants will: * Be assigned one of the two groups. * Use the oil topically once each day for 4 weeks. * Take one supplement in the morning and one in the evening every day for 4 weeks. * Attend 2 study visits in which they provide blood and urine (females only) samples. * Complete 2 stool collection/microbiome kits * Complete surveys and subjective health assessments
Detailed description
Digestive function plays a central role in daily comfort, quality of life, and overall well-being, even among generally healthy individuals. Many commercially available products are marketed to support normal digestive processes and gastrointestinal comfort; however, controlled human data evaluating their use under typical conditions in healthy populations remain limited. This study is designed to evaluate the tolerability, feasibility, and potential digestive-related effects of DigestZen when used as directed in a real-world context. DigestZen is a proprietary essential oil blend composed of Ginger, Peppermint, Caraway, Coriander, Anise, and Fennel essential oils, ingredients traditionally used to support digestive comfort and normal gastrointestinal function.
Interventions
DIETARY_SUPPLEMENTessential oil supplement
Internal use will entail ingesting Hypromellose capsules containing 135 mg essential oil and 365 mg extra virgin oil. The essential oils in the supplement are peppermint, coriander, ginger, caraway, cardamom, fennel, and anise. Participants will be instructed to take one capsule in the morning with food and one capsule in the evening with food, at least 3 hours before bedtime. Placebo will be olive oil capsules of the same size and color.
OTHEREssential Oil
Topical use will entail applying the DigestZen oil blend diluted to 10% in fractionated coconut oil using a metered dropper. Participants will be instructed to add 2mL to the skin of the inner forearms and belly area and massage until oil has absorbed. The application will happen once per day at bedtime. Placebo will contain fractionated coconut oil with a diluted single constituent for aroma and food coloring.
DIETARY_SUPPLEMENTPlacebo supplement
Placebo will be olive oil capsules of the same size and color as the active capsules.
OTHERplacebo essential oil
Placebo essential oil will contain fractionated coconut oil with diluted single constituent for aroma and food coloring.
Sponsors
dōTERRA International
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* 18-45 years old * Willing to attend 2 study visits at Prime Meridian Health Clinic in Pleasant Grove, Utah * Willing and able to undergo 2 blood draws over 4 weeks * Willing to provide urine (females) and stool samples twice over 4 weeks * Willing to wash out of all internally and topically used essential oils or botanical products for at least 2 weeks prior to starting the study, and willing to maintain the washout for the duration of the study (4 weeks) * Willing and able to use study products as directed daily for about 4 weeks * Willing to avoid alcohol, recreational drugs, tobacco, and vaping for the duration of the study * Willing to track use of study products * Willing to maintain current sleep, diet, and exercise habits for the duration of the study * No major diseases under treatment by doctor (Medical Reviewer's discretion) * No pregnancy within the last 90 days or currently breastfeeding, or possibility of becoming pregnant. * No allergy to any of the ingredients in the study products * No regular consumption of the study products within the last 1 month * No alcohol, recreational drug, tobacco, or vaping use in the past 1 month * No evidence of medical condition, significant disease or disorder, medication, or surgery within the past 12 months that may, in the judgement of the medical provider, put the participant at risk or affect study results, procedures, or outcomes. * Not currently or previously participating in another clinical trial within the last 30 calendar days.
Exclusion criteria
* Failure to meet all listed inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GSRS | 4 weeks | Looking for within- and between treatment changes to Gastrointestinal Symptom Rating Scale (GSRS) from baseline to completion. The GSRS uses a 7-point Likert scale for the 15 questions regarding gastrointestinal symptoms with answers ranging from "No discomfort at all" to "Very severe discomfort." Scores range from 15 to 105, and the total score is the sum of all item scores. Higher scores indicate more severe GI symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gene expression | 4 weeks | Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850K array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another. |
| Complete blood count (CBC) | 4 weeks | Change from baseline to Day 30 in white blood cell count and differential as measured by complete blood count. |
| Gut microbiome test | 4 weeks | Participants complete stool collection kits. Stool is analyzed for gut microbiome composition (e.g. bacteria %/count/type) |
| Digestion-associated Quality of Life Questionnaire (DQLQ) | 4 weeks | Validated, self-reported scale for the measurement of digestion-associated quality of life outcomes. The DQLQ is a 9-item scale with total scores between 0 and 9. Each item is scored as a percentage 0-100, with 100 representing a score of 1. Higher scores indicate greater dissatisfaction with digestion-associated quality of life outcomes. |
| PROMIS Global Health survey | 4 weeks | Validated, self-reported scale that assesses overall health-related quality of life across physical, mental, and social domains. The PROMIS Global Health Survey (v1.2) is a 10-item scale, with items scored between 1 and 5 each. Higher scores are indicative of a healthier person, with exceptions to the questions related to fatigue where a higher score indicates greater fatigue. |
| Adverse events | 4 weeks | This study will monitor the occurrence and frequency of adverse events and safety, both through participant report and blood chemistry/hematology/pregnancy testing (females). |
| Albumin (g/dL) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Blood urea nitrogen (BUN) (mg/dL) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Creatinine (mg/dL) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Alkaline phosphatase (U/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Alanine transaminase (ALT) (U/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Aspartate aminotransferase (AST) (U/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Calcium (mg/dL) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Carbon dioxide (mmol/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Chloride (mmol/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Potassium (mmol/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Sodium (mmol/L) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Total bilirubin (mg/dL) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
| Total protein (g/dL) | 4 weeks | Item in comprehensive metabolic panel for safety assessment |
Countries
United States
Contacts
CONTACTNicole Stevens
CONTACTRussell Osguthorpe
PRINCIPAL_INVESTIGATORNicole Stevens
doTERRA International LLC
Outcome results
None listed